KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy

Abstract

LEV monotherapy was not superior to standard AEDs for the global outcome, namely time to treatment withdrawal, in patients with newly diagnosed focal or generalised seizures.

Specific adverse effects of antiepileptic drugs — A true-to-life monotherapy study

“…Levetiracetam was significantly associated with five AEs out of which three -anger/aggression, nervousness/agitation, and depression -were confirmative [20][21][22][23][24]. Sleep disturbances so far have been reported only occasionally [21,25] and probably are not in the focus of physicians' attention.…”

“…In randomized controlled trials including valproic acid as treatment for patients with newly diagnosed epilepsy, tremor was reported spontaneously by patients most often with this AED [24,33].…”

Idiopathic generalised epilepsy of late onset: a separate nosological entity?

“…Although there are as yet no Class I studies comparing the efficacy of VPA with other AED in IGE, two large class III studies (SANAD B and KOMET trial) confirmed its good efficacy and tolerability in these syndromes, supporting VPA as the first choice in IGE 22 23…”

An update of the Hong Kong Epilepsy Guideline: consensus statement on the use of antiepileptic drugs in Hong Kong

“…Both studies demonstrated that LEV was as efficacious as the other standard regimens. 4,5 The evidence in the paediatric population was generally positive. 3,4,6,7 At the opposite end of the spectrum, geriatric patients were also shown in a Class II study to benefit from LEV monotherapy.…”